Safety of lamivudine treatment for chronic hepatitis B in early pregnancy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

409

HTML

3305

Figures (1-1)

242

Tables (1-2)

198

Sum=4154

Dec 7, 2012 (publication date) through Dec 3, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2012; 18(45): 6645-6650
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6645

Table 1 Clinical information of mothers who took lamivudine treatment before or during early pregnancy n (%)

	Treated population (n = 92)
Average age (yr)	30.5 ± 3.1
Primipara	88 (95.7)
Cirrhosis	2 (2.2)
HBeAg positivity rate	74 (80.4)
HBV DNA > 10⁵ copies/mL in early pregnancy	16 (17.4)
Treatment before pregnancy
Naive	15 (16.3)
LAM	41 (44.6)
ADV	28 (30.4)
LAM→ADV	3 (3.3)
ETV	2 (2.2)
ETV→ADV	1 (1.1)
IFN + LdT	2 (2.2)

LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir; LdT: Telbivudine; IFN: Interferon; HBeAg: Hepatitis B e antigen.

Citation: Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol 2012; 18(45): 6645-6650
URL: https://www.wjgnet.com/1007-9327/full/v18/i45/6645.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i45.6645